source
- Shionogi makes $2B rare disease play with IntraBio buyWith its acquisition of IntraBio, Shionogi will gain ownership over Aqneursa, which could hit peak global sales of $1 billion across its two indications in Niemann-Pick disease type C and ataxia-te…BioSpace · 15d ago↗ source
- FDA extends review of Novo’s hemophilia A drug, citing manufacturing issuesDespite the regulatory delay, Novo is still expecting a 2027 launch for its hemophilia A drug denecimig.BioSpace · 15d ago↗ source
- Vaxcyte's next-gen pneumococcal vaccine matches leading shots in Phase 3 trialVaxcyte reported that its experimental pneumococcal vaccine, VAX-31, achieved its primary efficacy goals in the first of three Phase 3 studies. In adults aged 50 and older, the vaccine performed o…